Stockscreener 앱 받기
28.02
0.43%
0.12
시간 외 거래:
27.89
-0.13
-0.46%
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? - Benzinga
Summit Therapeutics Q1 Loss Narrower Than Expected, Sales Nil - MSN
Why Summit Therapeutics Inc. (SMMT) Soared Last Week - Insider Monkey
These 10 Firms Soared Last Week, Here’s Why - Insider Monkey
Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025 - MSN
Summit Therapeutics (SMMT) Stock: Goldman Sachs Raises Price Target | SMMT Stock News - GuruFocus
Summit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating - TipRanks
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2025 Earnings Call Transcript - Insider Monkey
This Soaring Stock Just Delivered More Good News. Time to Buy? - The Globe and Mail
Summit Therapeutics (SMMT) Advances with Ivonescimab in Key Tria - GuruFocus
Summit Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Summit Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Press Release Distribution & PR Platform - ACCESS Newswire
Summit Therapeutics (SMMT) Beats Q1 Earnings Expectations - GuruFocus
Summit Therapeutics Inc Reports Q1 2025 EPS of $(0.09), Aligning with Estimates; Revenue Unreported - GuruFocus
Summit Therapeutics Reports Q1 2025 Financial Results - TipRanks
Summit Therapeutics Reports Financial Results and Operational Pr - GuruFocus
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 | SMMT Stock News - GuruFocus
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025 - Business Wire
Summit Therapeutics (SMMT) Sees Balanced Options Activity Ahead - GuruFocus
Summit Therapeutics (SMMT) Earnings Report Expected Amidst Mixed Forecasts - GuruFocus
Summit Therapeutics (NasdaqGM:SMMT) Sees 16% Stock Price Increase Over Past Month - Yahoo Finance
Why Is Summit Therapeutics Stock Trading Higher On Monday? - Benzinga
Summit Therapeutics, Intel among Monday’s market cap stock movers By Investing.com - Investing.com South Africa
Summit Therapeutics, Intel among Monday’s market cap stock movers - Investing.com
Summit Therapeutics stock holds $44 target despite drop - Investing.com
Summit Therapeutics stock holds $44 target despite drop By Investing.com - Investing.com India
Summit Therapeutics stock holds $40 target at Citizens JMP By Investing.com - Investing.com Canada
Summit Therapeutics stock holds $40 target at Citizens JMP - Investing.com
Summit Therapeutics Shares Tumble Amid Trial Data Concerns - TipRanks
Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market O - GuruFocus
Summit Therapeutics (SMMT) Maintains Buy Rating Despite Market Overreaction | SMMT Stock News - GuruFocus
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday? - MSN
Summit Therapeutics (SMMT) Shares Plummet After Survival Data Di - GuruFocus
Akeso survival data for ivonescimab misses expectations, STAT says - Yahoo Finance
Summit Therapeutics: New Ivonescimab Data Raise Concerns (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Stock Plummets Amid Study Setback - Evrim Ağacı
BioNTech And Summit Therapeutics Stocks Fluctuate Dramatically - Evrim Ağacı
Summit Therapeutics (SMMT) Reports Ivonescimab's Approval in Chi - GuruFocus
Summit Therapeutics (SMMT) Observes Notable Progress with Ivones - GuruFocus
Summit Therapeutics, Saia, And T-Mobile US Take A Hit In Trading - Finimize
Akeso (AKESF) and Summit Therapeutics (SMMT) See Stock Declines After Drug Data Release | BNTX Stock News - GuruFocus
Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials - TipRanks
Merck (MRK) Reacts to Summit Therapeutics' Lung Cancer Therapy D - GuruFocus
Market Today: Alphabet's Earnings Boost Tech, Summit Therapeutics Plummets - GuruFocus
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today - Mitrade
Summit Therapeutics (SMMT) Price Target Raised Amid Positive Dru - GuruFocus
0.33%
3.66%
자본화:
|
볼륨(24시간):